Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) in a report published on Tuesday, Benzinga reports. The brokerage currently has a $5.00 price objective on the biopharmaceutical company's stock.

Separately, StockNews.com started coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They set a "sell" rating for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $2.67.

Sangamo Therapeutics Stock Performance

Shares of Sangamo Therapeutics stock traded up $0.30 during trading hours on Tuesday, reaching $1.21. The company's stock had a trading volume of 65,541,019 shares, compared to its average volume of 6,337,115. The company has a market capitalization of $251.95 million, a P/E ratio of -0.88 and a beta of 1.23. Sangamo Therapeutics has a one year low of $0.29 and a one year high of $1.48. The stock's fifty day simple moving average is $0.86 and its two-hundred day simple moving average is $0.66.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The company had revenue of $0.36 million for the quarter, compared to analysts' expectations of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. As a group, research analysts forecast that Sangamo Therapeutics will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SGMO. State Board of Administration of Florida Retirement System raised its holdings in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 23,650 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Sangamo Therapeutics in the second quarter valued at approximately $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Sangamo Therapeutics in the second quarter valued at approximately $89,000. Vontobel Holding Ltd. lifted its position in Sangamo Therapeutics by 412.3% during the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company's stock valued at $259,000 after purchasing an additional 241,440 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Sangamo Therapeutics in the 1st quarter worth approximately $331,000. 56.93% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.